Accelerating Cures: Addressing Unmet Patient Need or Putting Patients at Risk

A confluence of scientific advances has exposed the biological basis of more diseases. These advances have enabled new approaches to drug development. It’s allowing us to target diseases in highly novel ways. We’ve been able to expose more maladies to targeted drug development. These methods are changing the contours of medical practice and the scope of human suffering. Regulatory policies are adapting to these opportunities, but slowly, and unevenly. We’re still allowing too many chances for big gains in human health to languish.

Click here to read the full publication →